Stockscreener 앱 받기
0.8257
2.47%
-0.0209
시간 외 거래:
.83
0.0043
+0.52%
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Jane Street Group LLC Trims Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (NASDAQ: ATOS) vs. NLS Pharmaceutics (NASDAQ: NLSP): A Comparative Analysis - HPBL
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
The Hidden Connection: Dr. Steven Quay on Alcohol and Cancer Risk - Cville Right Now
Atossa Therapeutics Applauds U.S. Surgeon General’s - GlobeNewswire
Surgeon General Links Alcohol to 44,000 Annual Breast Cancer Cases, Atossa Backs Warning - StockTitan
Geode Capital Management LLC Has $4.28 Million Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Barclays PLC Has $255,000 Stock Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
State Street Corp Has $2.63 Million Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd - Defense World
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
The Manufacturers Life Insurance Company Invests $75,000 in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update - MarketBeat
Atossa Therapeutics’ (ATOS) Buy Rating Reiterated at HC Wainwright - Defense World
Atossa Therapeutics to present poster on Z-endoxifen at SABCS - Yahoo Finance
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium - The Manila Times
Atossa Therapeutics to Present Poster Describing the - GlobeNewswire
Atossa Therapeutics Unveils Breakthrough Cancer Research: New Drug Combinations Show Enhanced Tumor-Fighting Power - StockTitan
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - The Manila Times
Atossa Therapeutics Announces Full Results from Phase 2 - GlobeNewswire
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically - EIN News
Atossa Therapeutics announces three posters on Phase 2 EVANGELINE trial - TipRanks
Atossa Therapeutics to Present Pharmacokinetic and - GlobeNewswire
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 - EIN News
Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.00 at Ascendiant Capital Markets - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Given New $7.00 Price Target at Ascendiant Capital Markets - MarketBeat
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research - The Manila Times
Atossa Therapeutics Presents Data from Study Investigating - GlobeNewswire
Atossa's New Breast Cancer Compounds Show Promising Anti-Cancer Activity in Latest Research - StockTitan
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research - The Manila Times
Atossa Therapeutics to Present New Cancer Treatment Research at AACR Conference | ATOS Stock News - StockTitan
Atossa Therapeutics announces five abstracts on Z-endoxifen - TipRanks
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - The Manila Times
Atossa's Endoxifen Breast Cancer Drug Data to Be Showcased at Major SABCS Conference | ATOS Stock News - StockTitan
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ATOS FY2024 EPS Estimate Increased by Cantor Fitzgerald - MarketBeat
What is HC Wainwright's Estimate for ATOS FY2026 Earnings? - MarketBeat
Atossa Therapeutics Inc (ATOS) Quarterly 10-Q Report - Quartz
Atossa Genetics stock target lifted, retains buy on positive study results - Investing.com UK
Atossa Therapeutics: Q3 2024 Financial Results and Updates - TipRanks
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Simply Wall St
Atossa Therapeutics (NASDAQ:ATOS) Downgraded to “Sell” Rating by StockNews.com - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go - Seeking Alpha
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Atossa Genetics shares hold Buy rating on positive trial results By Investing.com - Investing.com Canada
0.65%
4.62%
자본화:
|
볼륨(24시간):